Segmed
Segmed operates the Openda platform, providing de-identified multimodal medical imaging data and clinical datasets from a 2,800-site global network to pharmaceutical, medical device, and healthcare AI customers for regulatory-grade AI development and clinical research.
- Company typePrivate
- Founded2017
- HeadquartersPalo Alto, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Segmed does
Segmed operates a proprietary multimodal medical imaging data platform branded Openda that aggregates and de-identifies real-world imaging studies from a global network of 2,800+ healthcare partner sites across 50 U.S. states and 5 continents. The platform exposes approximately 150 million de-identified imaging studies spanning CT, MRI, X-ray, ultrasound, mammography, PET, SPECT, echocardiography, and DEXA modalities, with structured clinical data and radiology text available as longitudinal, device-diverse datasets. Core technical components include the Incognito de-identification pipeline (independently validated by a HIPAA Expert Determination), an LLM-based Data De-identification Playground, and a Quality Playground for AI model validation. The company holds SOC 2 Type II, ISO 27001, HIPAA, and GDPR certifications and positions its data as regulatory-grade for FDA submissions, claiming to have supported more than 35 FDA-cleared AI technologies.
Segmed firmographics
Firmographics- Name
- Segmed
- Legal name
- Segmed, Inc.
- Website
- https://segmed.ai
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Segmed operates the Openda platform, providing de-identified multimodal medical imaging data and clinical datasets from a 2,800-site global network to pharmaceutical, medical device, and healthcare AI customers for regulatory-grade AI development and clinical research.
- Ownership category
- akta.pro rank
Segmed industry classification
Industry- Product category
- Healthcare Imaging Data Platform
- NAICS
- Other Scientific and Technical Consulting Services (54169), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Healthcare Data Integration, ETL/ELT & Pipeline Orchestration (HLACAIAC)
- akta.pro secondary industries
- Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM), Data Linkage, Registries & Longitudinal Cohort Surveillance (HLAJANAM), FHIR/HL7 Data Repositories & Canonical Data Models (HLACAIAI)
Keywords
Where Segmed is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Segmed business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Data Licensing and Subscriptions: Segmed licenses de-identified medical imaging data to pharmaceutical companies, medical device manufacturers, AI developers, and healthcare researchers through subscription agreements and one-time data licensing contracts. Pricing varies based on dataset size, modality, customization requirements, and regulatory use case.
- Platform Access Fees: Revenue generated through access to the Openda platform for data exploration, cohort identification, and dataset procurement. Enterprise customers typically purchase imaging datasets or data subscriptions with aligned dataset delivery tied to AI training, validation, and regulatory timelines.
- Research Partnerships: Segmed generates revenue through research partnerships with life sciences companies and healthcare providers, providing data access and analytics services for clinical development and AI innovation programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise subscriptions for pharmaceutical, medtech, and AI companies requiring large-scale imaging datasets and regulatory-grade data access. |
| Subscription | Monthly | Self-serve platform access for smaller research teams and academic institutions through Openda. |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Segmed product offering
Product offeringCore offering
Segmed provides a proprietary multimodal data platform called Openda that aggregates and de-identifies approximately 150 million medical imaging studies from 2,800+ healthcare partner sites globally. The company licenses access to these regulatory-grade, HIPAA/GDPR-compliant datasets—spanning CT, MRI, X-ray, ultrasound, mammography, PET, SPECT, echocardiography, and DEXA—to pharmaceutical, medical device, and AI healthcare companies for clinical research, AI model training, and FDA regulatory submissions.
Product overview
Segmed offers a unified multimodal data platform called Openda that provides access to real-world medical imaging data and clinical insights for healthcare AI development and biopharmaceutical research. The platform includes solution modules for Life Sciences R&D, Medical Devices and AI R&D, Clinical Data Management, and Healthcare Providers, supported by tools like the LLM-based De-identification Playground and Quality Playground for AI validation. Segmed also provides specialized datasets including the DBT-2026 annotated breast imaging dataset, all designed to support FDA regulatory submissions and accelerate precision health innovation.
Differentiator
Problem solved
Functional benefit
Brands
- Openda: Proprietary data platform for accessing real-world medical imaging data for research and AI development
Products and services
- Openda Segmed's proprietary multimodal data platform providing access to approximately 150 million de-identified, regulatory-grade medical imaging studies across multiple modalities (CT, MRI, X-ray, ultrasound, mammography, PET, SPECT, echocardiography, DEXA) for healthcare AI development, biopharmaceutical research, and medical device innovation. Used by pharmaceutical, medtech, and AI companies for AI training, validation, and FDA regulatory submissions.
- DBT-2026 Annotated 3D Mammography Dataset Free open-source annotated Digital Breast Tomosynthesis (3D mammography) dataset released with iMerit and Advocate Health. Contains 558 female patients with biopsy-confirmed diagnoses (271 malignant, 287 benign), expert segmentation annotations in DICOM and JSON formats, and full de-identification for breast cancer AI research.
Quantifiable outcome
- 35+ FDA-cleared AI technologies supported by Segmed's datasets
- +3 more outcomes
Companies that use Segmed
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
Segmed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability8 records
Feature5 records
Segmed partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, flagship and supporting.
- iMeritcoreiMerit collaborated with Segmed and Advocate Health to release the largest open-source annotated breast tomosynthesis (3D mammography) dataset for AI research in breast cancer detection. The dataset comprises 558 female patients with biopsy-confirmed diagnoses (271 malignant, 287 benign). iMerit provided expert annotation and segmentation by domain specialists.
- Advocate HealthcoreAdvocate Health collaborated with Segmed and iMerit to provide imaging studies from their health system for the open-source breast tomosynthesis dataset. Advocate Health is one of the largest not-for-profit integrated health systems in the United States. Advocate Health also led Segmed's Series A funding round.
- Verily (Alphabet)flagshipSegmed partnered with Verily to make its de-identified, diagnostic-grade medical imaging data available within Verily's precision health research platform (Pre Exchange and Workbench). The collaboration enables researchers to access breast cancer datasets with digital breast tomosynthesis exams from Segmed's platform of approximately 150 million de-identified imaging exams. The partnership aims to lower barriers for researchers in academia, life sciences, and healthcare AI to accelerate precision health research and diagnostics development.
- BayercoreSegmed's real-world imaging data (RWiD) was integrated into Bayer's AI Innovation Platform to accelerate the development of AI-powered healthcare solutions. The partnership enables Bayer to leverage Segmed's diverse imaging datasets for pharmaceutical research and AI development.
- MicrosoftcoreSegmed collaborates with Microsoft on foundation model development for healthcare AI. At RSNA 2025, Segmed and Microsoft co-presented an AI Theater session on 'Preparing Medical Data for Foundation Models' and explored best practices for preparing clinical datasets for AI development while maintaining compliance and patient privacy.
- Beacon Health SystemsupportingSegmed announced partnership with Beacon Health System for medical data collaboration. Beacon Health System contributes imaging data to Segmed's platform for research and AI development purposes.
- DatavantsupportingSegmed partnered with Datavant to provide deeper patient insights through advanced imaging data integration. The partnership enables linking Segmed's imaging data with other healthcare data sources for comprehensive patient insights.
- MAPIsupportingMAPI partnered with Segmed to transform medical data into clinical impact in Japan. The partnership aims to leverage global medical data to accelerate AI-powered healthcare in the Japanese market.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
Segmed competitors and assessment
Company assessmentEmerging players
- Sirona Medical: Sirona Medical is an AI-native radiology operating system that aggregates imaging data and embeds diagnostic AI tools. It represents an emerging competitor integrating imaging AI directly into radiologist workflows, overlapping with Segmed's medical imaging data value chain.
- DeepHealth (Saama): DeepHealth (acquired by Saama) provides AI-powered medical imaging solutions and curated datasets for clinical and research applications. It overlaps with Segmed in supplying imaging datasets for AI development, particularly in oncology and radiology use cases.
Broad incumbents
- Datavant: Datavant specializes in health data linkage and de-identification, connecting disparate datasets for life sciences and healthcare. Segmed has a partnership with Datavant, but Datavant also competes in supplying linked real-world data for evidence generation and AI development.
- IQVIA: IQVIA is the largest life sciences RWE and clinical data provider, with extensive enterprise pharma relationships and a broad portfolio spanning real-world data, clinical trial services, and technology platforms. It is a broader incumbent competing for the same pharma data and evidence-generation budgets that Segmed targets.
- Health Catalyst: Health Catalyst offers a healthcare data and analytics platform for health systems and life sciences, including data warehousing and RWE capabilities. It overlaps with Segmed in healthcare data infrastructure and provider-sourced data monetization.
Direct peers
- TriNetX: TriNetX operates a global health research network providing de-identified clinical data for trial feasibility, cohort identification, and real-world evidence. It overlaps directly with Segmed's pharma R&D and clinical research use cases across multiple therapeutic areas.
- Tempus Labs: Tempus provides a multi-modal data library (including imaging, clinical, and molecular data) for AI development and pharma R&D. It is the most direct competitor to Segmed in supplying enterprise healthcare data for AI training and clinical research, with overlapping customer base in biopharma and AI developers.
- Owkin: Owkin builds AI models on medical imaging and multi-modal patient data, federated across hospitals. It competes with Segmed in supplying imaging data for healthcare AI, particularly for biopharma R&D and clinical research, with a strong presence in European academic medical centers.
- Aetion: Aetion provides a real-world evidence analytics platform used by biopharma and regulators for treatment effect estimation and regulatory-grade analyses. It serves the same life sciences R&D customer base as Segmed, focused on regulatory-grade evidence generation from real-world data.
- Flatiron Health: Flatiron Health aggregates de-identified oncology real-world data from clinics and EHRs for pharma evidence generation and FDA submissions. Like Segmed, it sells to biopharma for clinical development and RWE use cases, with comparable regulatory-grade data positioning.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Segmed social profiles
Digital presenceSegmed compliance and trust
Trust signalCompliance4 records
Segmed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Segmed leadership team
Management profileNumber of profiles
Profiles7 records
Segmed funding detail
Funding detailFunding overview
Funding rounds7 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Segmed M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Segmed
What does Segmed do?
Segmed provides a proprietary multimodal data platform called Openda that aggregates and de-identifies approximately 150 million medical imaging studies from 2,800+ healthcare partner sites globally. The company licenses access to these regulatory-grade, HIPAA/GDPR-compliant datasets—spanning CT, MRI, X-ray, ultrasound, mammography, PET, SPECT, echocardiography, and DEXA—to pharmaceutical, medical device, and AI healthcare companies for clinical research, AI model training, and FDA regulatory submissions.
Is Segmed a public or private company?
Segmed is a private company. It is classified as venture growth investor backed and is currently operating.
When was Segmed founded?
Segmed was founded in 2017. It employs 11 to 50 people.
Where is Segmed based?
Segmed is headquartered in Palo Alto, United States, in the North America region.
How does Segmed make money?
Three revenue lines are on record. Data Licensing and Subscriptions are the primary driver. The others are platform Access Fees and research Partnerships.
Who are Segmed's main competitors?
Emerging players on record are Sirona Medical and DeepHealth (Saama). Broad incumbents are Datavant, IQVIA and Health Catalyst. Direct peers are TriNetX, Tempus Labs, Owkin, Aetion and Flatiron Health.
Does Segmed have an API?
No public API is recorded for Segmed.
What industry is Segmed in?
Segmed's product category is Healthcare Imaging Data Platform. Its primary akta.pro industry code is HLACAIAC, Healthcare Data Integration, ETL/ELT & Pipeline Orchestration, with a secondary code of HLACABAM, Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity). Its NAICS code is 54169 and its SIC code is 7370.